Lakozamid Pliva (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing these channels, it reduces repetitive neuronal firing and hyper‑excitability, which are key mechanisms underlying seizure generation. This modulation helps to maintain normal electrical activity in the brain.

The specific dose of Lakozamid Pliva is determined by the prescribing clinician based on the patient’s age, weight, renal function, and response to therapy. Healthcare professionals follow established guidelines and titrate the dose to achieve optimal seizure control while monitoring for side effects.

Safety data for lacosamide in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss the uncertainties with patients and consider alternative treatments when appropriate.

To order Lakozamid Pliva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lakozamid Pliva (lacosamide) belongs to the sodium channel blocker class, offering a distinct mechanism that enhances slow inactivation of sodium channels. Compared with drugs that act on fast inactivation, lacosamide may provide better tolerability for some patients and can be combined with other antiepileptics for synergistic seizure control.

Lakozamid Pliva should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability and potency throughout its shelf life.

Lakozamid Pliva is administered orally, typically as a tablet or capsule taken with or without food. The exact dosing schedule—once or twice daily—depends on the prescriber’s instructions and the patient’s individual treatment plan.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, which can lead to arrhythmias, and rare but severe skin reactions like Stevens‑Johnson syndrome. Additionally, patients may experience suicidal thoughts; any emergence of mood changes should prompt immediate medical evaluation.

Lakozamid Pliva is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking medications that strongly affect CYP3A4 metabolism without appropriate monitoring.